HomeComparePPIPX vs MRK

PPIPX vs MRK: Dividend Comparison 2026

PPIPX yields 6.73% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PPIPX wins by $462.00 in total portfolio value
10 years
PPIPX
PPIPX
● Live price
6.73%
Share price
$20.24
Annual div
$1.36
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$1,032.28
Full PPIPX calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — PPIPX vs MRK

📍 PPIPX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPPIPXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PPIPX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PPIPX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PPIPX
Annual income on $10K today (after 15% tax)
$572.03/yr
After 10yr DRIP, annual income (after tax)
$877.44/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, PPIPX beats the other by $69.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PPIPX + MRK for your $10,000?

PPIPX: 50%MRK: 50%
100% MRK50/50100% PPIPX
Portfolio after 10yr
$31.0K
Annual income
$991.29/yr
Blended yield
3.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PPIPX
No analyst data
Altman Z
0.5
Piotroski
7/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PPIPX buys
0
MRK buys
0
No recent congressional trades found for PPIPX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPPIPXMRK
Forward yield6.73%3.25%
Annual dividend / share$1.36$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$31.2K$30.7K
Annual income after 10y$1,032.28$950.29
Total dividends collected$8.6K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PPIPX vs MRK ($10,000, DRIP)

YearPPIPX PortfolioPPIPX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,373$672.97$11,192$351.54+$181.00PPIPX
2$12,884$715.30$12,524$392.70+$360.00PPIPX
3$14,544$757.35$14,015$438.65+$529.00PPIPX
4$16,361$798.95$15,682$489.96+$679.00PPIPX
5$18,346$839.97$17,547$547.23+$799.00PPIPX
6$20,510$880.27$19,632$611.16+$878.00PPIPX
7$22,866$919.75$21,963$682.53+$903.00PPIPX
8$25,425$958.29$24,571$762.18+$854.00PPIPX
9$28,200$995.83$27,486$851.08+$714.00PPIPX
10$31,207$1,032.28$30,745$950.29+$462.00PPIPX

PPIPX vs MRK: Complete Analysis 2026

PPIPXStock

The investment seeks the highest total return over time consistent with a primary emphasis on income and a secondary emphasis on capital growth. The fund invests in a diversified portfolio typically consisting of approximately 40% stocks; 55% bonds, money market securities, and cash reserves; and 5% alternative investments, including through hedge funds. Under normal conditions, its allocation to the broad asset classes will be within the following ranges: stocks (30-50%), bonds, money markets securities, and cash reserves (45-65%), and alternative investments (0-10%).

Full PPIPX Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this PPIPX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PPIPX vs SCHDPPIPX vs JEPIPPIPX vs OPPIPX vs KOPPIPX vs MAINPPIPX vs JNJPPIPX vs ABBVPPIPX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.